Clinical benefits of lenograstim in patients with neutropenia due to chemotherapy for multiple myeloma (MM)

Supportive Care in Cancer

Volumn 9, Issue 5, 2001, Pages 397-399

  Takagi, T ^a   Sawamura, M ^b   Sezaki, T ^c   Kashimura, M ^d   Tsuchiya, J ^e   Hotta, T ^f   Ogawa, N ^g   Hirashima, K ^h  

^a CHIBA CANCER CENTER   (Japan)

^b National Nishigunma Hospital   (Japan)

^c National Hospital Organization   (Japan)

^d Matsudo Municipal Hospital   (Japan)

^e GUNMA UNIVERSITY   (Japan)

^f TOKAI UNIVERSITY   (Japan)

^g EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Average dose intensity; Compliance of the treatment; Lenograstim; MCNU VMP therapy; Multiple myeloma; Neutropenia

Indexed keywords

ANTINEOPLASTIC AGENT; MELPHALAN; PREDNISOLONE; RANIMUSTINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINDESINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; JAPAN; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; NEUTROPENIA; NITROSOUREA COMPOUNDS; PREDNISOLONE; RECOMBINANT PROTEINS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VINDESINE;

EID: 0034913585     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200000223     Document Type: Article

References (10)

1. The treatment of multiple myeloma
2. Effective treatment of advanced multiple myeloma refractory to alkylating agents
3. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisolone even in high-risk patients
4. The importance of dose intensity in chemotherapy of metastatic breast cancer
5. Effect criteria of chemotherapy: Myeloma
6. Combination chemotherapy with MCNU, vindesine, melphalan, and prednisolone (MCNU-VMP therapy) in induction therapy for multiple myeloma
7. Purification and characterization of human granulocyte colony-stimulating factor (rG-CSF)
8. A randomized controlled study of granulocyte colony-stimulating factor after intensive induction and consolidation therapy in patients with acute lymphoblastic leukemia
9. Biologic activity of MCNU: A new antitumor agent
10. MCNU-VMP therapy: A new nitrosourea-based combination chemotherapy for multiple myeloma